Nature 1995
This dual GLP-1 and GIP receptor agonist, licensed in the UK for type 2 diabetes and weight management, can cause dizziness through several mechanisms including blood glucose fluctuations, blood pressure changes, and gastrointestinal effects leading to dehydration
What about you
Genetic variability, unique disease characteristics, or unknown factors
Links to other articles on this website with more advanced information and tips related to this medication and/or related topics are provided below, under Related Pages FDA indications According to the Prescribing Information, the wording of the FDA-approved indications for tirzepatide injection (Zepbound ) are as follows (the emphasis below in red has been added by us): ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition
Vitamin injections are ideal for individuals who feel fatigued, struggle with mood swings, get sick often, or have difficulty losing weight
